# ProKidney (PROK) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/PROK
## Company Profile
- Ticker: PROK
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 1.92 USD
- Market cap: 389879454.7 USD
- Last updated: 2026-09-03
## Business Overview
### Regenerative Kidney Medicine
ProKidney develops cell therapies intended to preserve kidney function and delay progression to kidney failure. Its work focuses on patients with advanced chronic kidney disease and type 2 diabetes who face a high risk of dialysis or transplantation.
### Rilparencel
Rilparencel, also known as REACT, is a proprietary autologous cell therapy manufactured from a patient's own kidney cells. The product has Regenerative Medicine Advanced Therapy designation and is designed to restore or stabilize kidney function through repeat image-guided injections.
### Phase 3 Development
The Phase 3 REGEN-006, or PROACT 1, study evaluates rilparencel against a sham procedure. Its design supports an accelerated-approval analysis based on annualized eGFR slope and a longer confirmatory analysis based on kidney-function decline, dialysis, transplantation, or renal and cardiovascular death.
## Why The Stock Is Moving

As of Sep 3, 2026, PROK closed up 0.52% at $1.92. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of full enrollment in the Phase 3 REGEN-006 study in the second half of 2026.
- Topline results from the accelerated-approval efficacy analysis of REGEN-006 in the second quarter of 2027.
- Topline results from the confirmatory composite time-to-event analysis of REGEN-006 in the second half of 2029.

## Drug Assets

- rilparencel

## Recent News
- 2026-08-10 20:05 EST — [ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/PROK/prokidney-reports-second-quarter-2026-financial-results-and-business-highlights-56311737) — Source: ProKidney
- 2026-06-02 12:00 EST — [ProKidney Appoints Kenneth Locke as Chief Technical Officer](https://biopharmsignal.com/news/PROK/prokidney-appoints-kenneth-locke-as-chief-technical-officer) — Source: ProKidney
- 2026-05-15 15:45 EST — [ProKidney Reports First Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/PROK/prokidney-reports-first-quarter-2026-financial-results-and-business-highlights) — Source: ProKidney
- 2026-03-25 20:01 EST — [ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer](https://biopharmsignal.com/news/PROK/prokidney-expands-senior-leadership-team-with-appointment-of-greg-madison-as-chief-commercial-officer) — Source: ProKidney
- 2026-03-18 20:00 EST — [ProKidney Reports Full Year 2025 Financial Results and Business Highlights](https://biopharmsignal.com/news/PROK/prokidney-reports-full-year-2025-financial-results-and-business-highlights) — Source: ProKidney